New shingles vaccine trial aims to protect millions over 40
NCT ID NCT06851832
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new shingles vaccine in 960 healthy adults aged 40 and older. The goal is to see if it is safe and triggers a strong immune response. Researchers will monitor side effects and measure antibody levels over time. This is an early-stage trial to help develop a better vaccine against shingles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HERPES ZOSTER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xiangcheng County Center for Disease Control and Prevention
Xuchang, Henan, China